{"id":"7898e47d82c4","type":"article","url":"https://hartvaat.nl/2024/06/01/s2i2n0-3-score-voorspelt-mortaliteit-bij-hfref-guide-it-subanalyse/","title":"S2I2N0-3 score voorspelt mortaliteit bij HFrEF: GUIDE-IT subanalyse","title_en":"S2I2N0-3 score predicts short- and long-term mortality and morbidity in HFrEF: a post-hoc analysis of the GUIDE-IT trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.14689","source_url":"https://doi.org/10.1002/ehf2.14689","authors":["Junyi Sun","Zhengshuo Xie","Min Ye","He Xu","Yugang Dong","Chen Liu","Wengen Zhu"],"significance":5,"published":"2024-06-01","source_date":"2024-06-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/"],"congress":"","summary_en":"Post-hoc analysis of the GUIDE-IT trial validated the S2I2N0-3 score — incorporating stroke history, insulin-treated diabetes, and NT-proBNP — as a reliable predictor of short- and long-term mortality and morbidity in patients with heart failure with reduced ejection fraction.","created":"2026-07-03T10:30:57Z","updated":"2026-07-03T13:29:59Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Subanalyse van GUIDE-IT valideerde de S2I2N0-3 score als prognostische marker bij HFrEF. De composietscore van klinische parameters voorspelde kort- en langetermijnmortaliteit betrouwbaar.","abstract_original":"AIMS: This study investigated the S2I2N0-3 score, a simple tool comprising stroke history, insulin-treated diabetes, and N-terminal pro-brain natriuretic peptide, for forecasting mortality and morbidity in heart failure (HF) with reduced ejection fraction (HFrEF). METHODS AND RESULTS: Analysing 890 GUIDE-IT HFrEF trial participants, we stratified them by baseline S2I2N0-3 risk score into three risk groups. We examined the score's association with five adverse outcomes over short (90 days) and extended periods (median follow-up of 15 months) using Cox and competing risk models. Our analysis revealed significant positive associations between the S2I2N0-3 strata and adverse outcomes. When analysed as a continuous variable, each point increment of the S2I2N0-3 score was associated with a higher risk of short- and long-term cardiovascular death [short term: hazard ratio (HR) 1.43, 95% confidence interval (CI) 1.03-1.98; long term: HR 1.18, 95% CI 1.02-1.38], all-cause death (HR 1.52, 95% CI 1.12-2.07; HR 1.18, 95% CI 1.03-1.36), HF hospitalization (HR 1.39, 95% CI 1.20-1.62; HR 1.18, 95% CI 1.06-1.31), any hospitalization (HR 1.19, 95% CI 1.06-1.34; HR 1.09, 95% CI 1.00-1.19), and the composite outcome of cardiovascular death and HF hospitalization (HR 1.39, 95% CI 1.21-1.60; HR 1.17, 95% CI 1.06-1.30). The S2I2N0-3 demonstrated reliable prognostic value, with C-indices ranging from 0.619 to 0.753 across outcomes and time points. When compared with the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score using Z-statistics, net reclassification index, and integrated discrimination improvement, the S2I2N0-3 showed comparable predictive power for all outcomes during both short- and long-term follow-ups. CONCLUSIONS: The S2I2N0-3 risk score had modest predictive values for both short- and long-term clinical outcomes in HFrEF patients, offering equivalent performance to the established MAGGIC score."}